Renovorx, INC Form 4 insider transactions

Director Una S. Ryan acquired shares of RenovoRx common stock through distributions from investment funds.

RenovoRx Chief Financial Officer Mark Voll reported the acquisition of 25,000 common shares and the vesting of 8,823 restricted stock units.

RenovoRx, Inc. CEO Shaun Bagai has been granted nearly 1 million stock options with a four-year vesting schedule starting January 2026.

RenovoRx Chief Financial Officer Mark Voll received a grant of 80,000 restricted stock units as compensation for past and future services.

RenovoRx, Inc. has issued 128,550 stock options to its Chief Clinical Officer, Leesa Gentry, as part of a long-term incentive and retention strategy.

RenovoRx, Inc. has granted Chief Medical Officer Ramtin Agah options to purchase 621,727 shares at an exercise price of $0.98.

RenovoRx's Chief Financial Officer, Mark Voll, was granted 12,380 restricted stock units for his consulting services.

RenovoRx Director Laurence Marton acquired common stock and warrants in a private placement, increasing his beneficial ownership.

RenovoRx CEO Shaun Bagai acquired 24,300 shares of common stock and 12,150 warrants in a private placement for $25,000, increasing his beneficial ownership.

RenovoRx's Chief Financial Officer, Mark Voll, acquired 97,200 common shares and 48,600 warrants in a private placement.

RenovoRx's Chief Medical Officer and Director, Ramtin Agah, acquired 10,000 shares of common stock in an open market transaction.

RenovoRx's Chief Medical Officer, Ramtin Agah, acquired 9,795 shares of common stock at $0.86 per share in an open market transaction.

RenovoRx's Chief Medical Officer, Ramtin Agah, filed a Form 4 disclosing a planned open market purchase of 205 common shares on December 30, 2025, under a 10b5-1 plan.

RenovoRx, Inc. CEO Shaun Bagai purchased 5,000 shares of common stock in an open market transaction.

RenovoRx, Inc. CEO Shaun Bagai purchased 5,000 shares of common stock in an open market transaction at $0.8524 per share.

RenovoRx Chief Medical Officer Ramtin Agah purchased 12,000 shares of common stock in an open market transaction.

RenovoRx's Chief Medical Officer, Ramtin Agah, acquired 10,000 shares of common stock in an open market transaction.

RenovoRx's Chief Medical Officer, Ramtin Agah, increased his direct beneficial ownership of common stock through two open market purchases in late November 2025.

RenovoRx, Inc. Director Laurence Marton received a grant of 47,640 stock options with an exercise price of $1.34, vesting monthly over 12 installments.

RenovoRx Director K. Angela Macfarlane was granted 47,640 stock options with an exercise price of $1.34, vesting over 12 months.

RenovoRx Director Una S. Ryan was granted 47,640 stock options with an exercise price of $1.34, vesting over 12 months starting November 1, 2025.

RenovoRx, Inc. Director Robert J. Spiegel was granted 47,640 stock options with an exercise price of $1.34, vesting over 12 months.

RenovoRx, Inc. CEO Shaun Bagai increased his direct ownership in the company through open market purchases of common stock.

RenovoRx, Inc. has granted 63,636 non-qualified stock options to its Chief Medical Officer and Director, Ramtin Agah, under the company's Amended and Restated 2021 Omnibus Equity Incentive Plan.

RenovoRx, Inc. CEO Shaun Bagai has been granted 102,498 stock options, vesting over four years, following stockholder approval of an increase in the company's equity incentive plan.

RenovoRx, Inc.'s Chief Clinical Officer, Leesa Gentry, was granted 6,619 stock options with an exercise price of $1.27, vesting over four years.

RenovoRx, Inc. has granted 41,600 incentive stock options to Ron Kocak, VP, Controller and PAO, under its 2021 Omnibus Equity Incentive Plan, with vesting commencing January 1, 2025.

RenovoRx, Inc.'s Chief Medical Officer and Director, Ramtin Agah, reported an open market purchase of 21,000 shares of common stock on June 5, 2025, increasing his beneficial ownership to 734,460 shares.

Ramtin Agah, Chief Medical Officer and Director of RenovoRx, Inc., reported a gift of 400,000 shares of common stock to trusts for his children, reducing his direct beneficial ownership.

Laurence Marton, a director of RenovoRx, Inc., exercised stock options to acquire 20,480 shares of common stock at $0.15 per share on May 2, 2025.